Tenofovir-Emtricitabine-Efavirenz in HIV-I-Infected Adults in Senegal: A 96-Week Pilot Trial in Treatment-Naive Patients

Abstract

We report the results of a pilot open-label trial of a tenofovir (TDF)/emtricitabine (FTC)/efavirenz (EFV) combination conducted in Dakar, Senegal. Forty HIV-1-infected patients, naive of antiretroviral treatment and without active opportunistic disease, were included and followed through 96 weeks. At weeks 48 and 96, respectively, 82.5% and 85% of patients had HIV-1 RNA <400 copies/mL (72.5% and 77.5% with HIV-1 RNA <50 copies/mL). Between baseline and week 96, the mean (SD) CD4 count increased from 126 (102) to 338 (155) cells/mm³. The mean (SD) creatinine clearance decreased from 92 (36) to 73 (19) mL/min (P = .001). Treatment adherence was at least 94% at all scheduled visits. The efficacy and tolerability of a TDF/FTC/EFV combination were high and similar to those observed in Northern countries. This drug combination can be recommended in limited-resource countries, as did the World Health Organization (WHO) and should be made readily available as a fixed-dose combination.

Keywords

HAART HIV-1 sub-Saharan Africa tenofivir emtricitabine efavirenz safety first-line treatment

References

Merson MH The HIV-AIDS pandemic at 25-the global response. N Engl J Med. 2006;354(23):2414-2417.

Van Damme W. , Kober K. , Laga M. The real challenges for scaling up ART in sub-Saharan Africa. AIDS. 2006;20(5):653-656.

Ferradini L. , Jeannin A. , Pinoges L. , et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367(9519):1335-1342.

Laurent C. , Ngom Gueye NF , Ndour CT , et al., and the ANRS 1215/1290 Study Group. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr. 2005;38(1):14-17.

Danel C. , Moh R. , Anzian A. , et al. Tolerability and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr. 2006;42(1):29-35.

Lyseng-Williamson KA , Reynolds NA , Plosker GL Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs. 2005;65(3):413-432.

Gallant JE , DeJesus E. , Arribas JR , et al., for the Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251-260.

WHO Antiretroviral therapy for HIV infection in adults et adolescents in resource limited settings: toward universal access. Recommendations for a public health approach. http://www.who.int. Accessed September 7th, 2009.

Cockcroft DW , Gault MH Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.

10.

Landman R. , Schiemann R. , Thiam S. , et al., and the Imea 011/ANRS 12-04 Study Group. Once-a-day highly active antiretroviral therapy in treatment-naïve HIV-1-infected adults in Senegal. AIDS. 2003 ;17(7):1017-1022.

11.

Etard JF , Ndiaye I. , Thierry-Mieg M. , et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20(8):1181-1189.

12.

Riddler SA , Haubrich R. , DiRienzo AG , et al., for the AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095-2106.

13.

Mauss S. , Berger F. , Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction . AIDS. 2005;19(1):93-95.

14.

Gallant JE , Parish MA , Keruly JC , Moore RD Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment . Clin Infect Dis. 2005;40(8):1194-1198.

15.

Izzedine H. , Hulot JS , Vittecoq D. , et al., for the Study 903 Team. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20(4):743-746.

16.

Malik A. , Abraham P. , Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature. J Infect. 2005;51(2):E61-E65.

17.

Nelson MR , Katlama C. , Montaner JS , et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21(10):1273-1281.

18.

Reid AJC Glomerular dysfunction and associated risk factors following initiation of ART in Africa: a subanalysis in the DART Trial [oral presentation]. Paper presented at: 16th International AIDS Conference; August 13-18, 2006; Toronto , Canada.

19.

Mwango A. , Gigant M. , Mulenga L. , et al. First-line Tenofovir ART: Zambia. Paper presented at: 16th Conference on Retroviruses and Opportunistic infections; February 8-11, 2009; Montreal, Canada.

20.

Beck EJ , Vitoria M. , Mandalia S. , Crowley S. , Gilks CF , Souteyrand Y.

National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines?

AIDS. 2006;20(11):1497-1502.